Dr Özlem Türeci
Dr Özlem Türeci, M.D., Co-Founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience.
Dr Türeci has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf vaccine candidates and other types of immunotherapies which are currently in clinical development. Dr Türeci leads the clinical development of BioNTech’s “Project Lightspeed,” the company’s successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year.
Dr Türeci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. The company was acquired by Astellas in 2016. She currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recent recipient of the German Sustainability Award, among other notable recognitions. Dr Türeci is married to Prof Ugur Sahin.
Dr Stephen Lockhart
Dr Stephen Lockhart is Vice President and Head of Europe and Asia-Pacific Vaccine Clinical Research and Development (VCRD) at Pfizer.
Dr Lockhart qualified as a physician in 1980, trained in hospital internal medicine and research and then joined the pharmaceutical industry in 1986. Dr Lockhart has over 30 years of experience in pharmaceutical and vaccine development. His roles include senior positions in Vaccine Development at Lederle Praxis Biologicals, Wyeth Vaccine Research, Emergent BioSolutions, Sanofi Pasteur MSD and now Pfizer. He has worked on development of vaccines against influenza, anthrax and tuberculosis to name a few as well as paediatric combination vaccines. He currently leads Pfizer’s clinical activities on various vaccines including the Pfizer/BioNTech mRNA COVID-19 vaccine.
He received his MA from the University of Cambridge and BM, BCh and a research based doctoral degree, DM, from the University of Oxford. He received a Diploma in Pharmaceutical Medicine, is a Member of the Royal College of Physicians UK (MRCP) and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM).
Two of the leading lights from the dark days of the COVID-19 pandemic will guide us through their journey in developing the BioNTech/Pfizer vaccine and the logistics of getting it into the arms to the world. Dr Türeci will examine the potential of mRNA technology underlying the vaccine and its potential application to other therapies. Dr Lockhart will focus on how companies, regulators and healthcare providers can best collaborate for effective, fast product roll-out during future public health emergencies.
Dr June Raine
Dr June Raine is the Chief Executive of the Medicines and Healthcare products Regulatory Agency. Dr Raine trained in general medicine in Oxford after completing a Master’s degree by research in pharmacology. Her interest in drug safety led to a career in medicines regulation from 1985 onwards.
Dr Raine has extensive experience and knowledge of the Agency’s work, gained in a number of different licensing and post-licensing roles, and was Director of the Vigilance and Risk Management of Medicines division from 2006. Her experience includes chairing the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency for six years. She is also a member of the WHO Advisory Committee on Safety of Medicinal Products.
Dr June Raine will speak of some of the MHRA’s experiences and learnings during the pandemic and how the MHRA will build on this for the future. Covering topics as diverse as medical devices, patient engagement, and the use of real world evidence and digital health, Dr Raine will describe her vision for how the MHRA can play a leading role in the innovation of medicines development, and how the UK can best pivot to foster the evolving relationship with global regulators, post-Brexit.
Dr Sheuli Porkess
Dr Sheuli Porkess is the Director of Actaros Consultancy, an experienced pharmaceutical physician and is the former Director of Research, Medical and Innovation at the Association of the British Pharmaceutical Industry. Sheuli’s career began in clinical medicine in the NHS and includes a number of medical leadership roles in companies.
Sheuli has expertise in policy development within the UK and internationally and is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and a Global Fellow in Medicine Development with IFAPP.
Dr Craig Hartford
Dr Craig Hartford is an independent Pharmaceutical Physician with special interest in Medicines/Medical-Devices Benefit-Risk Management & Pharmacovigilance. He graduated MB BCh, MSc Med, PhD and held full-time academic/research posts until 1998. He then joined Pfizer R&D and in 2010-2019 was Vice President in Drug Safety at Pfizer, overseeing Safety Signal Detection/Evaluation and Benefit-Risk Management for 700+ products across the product drug lifecycle. He is an FPM Appraiser and a committee member for our Policy and Communications Group and member of our Government and Healthcare Policy Expert Group. He holds a GMC License to Practise Pharmaceutical Medicine.
Dr Neil Snowise
Dr Neil Snowise worked at GSK for 11 years, initially in Medical Affairs and subsequently as a Director in Respiratory Clinical Development. He was Project Physician Leader for a novel drug in asthma at GSK, before taking on new challenges as the Medical Director at Vectura – a clinical development company specialising in inhaled products for respiratory disease. Neil has an MSc in Pharmaceutical Medicine from Surrey University and he continues clinical practice as Honorary Clinical Fellow in Respiratory Medicine for a weekly hospital clinical session. He has contributed to a number of journals over the years, including Pharmaceutical Physician.
Dr Susan Tansey
Dr Susan Tansey has more than 20 years’ experience in clinical trials in several therapeutic areas including vaccine research and rare diseases, both in pharmaceutical companies and latterly in contract research organisations (CROs). Prior to this, Susan trained in paediatrics in the NHS for nine years. She is currently working as an independent consultant pharmaceutical physician and holds a Certificate of Completion of Specialist Training (CCST) in Pharmaceutical Medicine. She was recently appointed as a member of the Nuffield Council on Bioethics.
Dr Dave Leather
Dr Dave Leather joined GSK in 2000 and is currently Medical Vice President and Global Head of Inhaled Asthma Therapies in the Specialty and Primary Care Therapy Area. He leads a team of physicians and scientists who support GSKs medicines and who develop trial designs. He is particularly interested in real-world pragmatic trials and led the internationally recognised Salford Lung Study. Originally a primary care physician in Bolton with an interest in respiratory disease, Dave managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. Dave also worked as a media doctor for the BBC and commercial radio.
Dr John Ndikum
Dr John Ndikum holds medical and neuroscience degrees from the University of London and a Masters in Public Health from Yale University. He works in general medicine with a focus on internal and pharmaceutical medicine, the latter for which he serves as a Principal Investigator for Alzheimer’s Disease. John is General Secretary for the public health organization ‘Inspiral Health’ as well as a public health advisor for Rotary International, with whom he secured a scholarship to attend Yale. He provides mentorship and coaching through his burgeoning social enterprise ‘Zero Entropy Consulting’.
Dr David Jefferys
Dr David Jefferys is currently Senior Vice president in Eisai, responsible for Global Regulatory, Government Relations, Public Affairs and Product Safety. After qualifying in medicine, he practised as a physician and cardiologist, with additional interests in metabolic medicine and clinical toxicology. He spent 21 years as a senior regulatory in the UK and Europe. He was executive director of licensing in MCA, CPMP member, chairman of the MRFG and PER committees. He was CEO and Director of the
UK Medical Devices Agency and on the creation of the MHRA acting joint chief executive. He worked on secondment at the EMEA /EMA on benefit risk methodologies.
Professor Peter Stonier
Professor Peter Stonier is Director of Speciality Training at the Faculty of Pharmaceutical Medicine & national Programme Director for pharmaceutical medicine specialty training for pharmaceutical & regulatory physicians in UK. He is a Board Member of the PharmaTrain Federation, developing & introducing internationally a platform of education & training for all in medicines development / clinical research: industry, academia, clinical trial investigators.
Peter was a founding Fellow of the Faculty of Pharmaceutical Medicine (FPM), Royal Colleges of Physicians UK (1989), & with others made a major contribution to achieving recognition & legal listing for the medical Specialty of Pharmaceutical Medicine in 2002.
Professor Tim Higenbottam
Professor Tim Higenbottam is the current FPM President and a giant of our specialty. Whilst working as an NHS Consultant at Papworth Hospital, Cambridge he developed intravenous prostacyclin (the first therapy to improve survival in idiopathic Pulmonary Arterial Hypertension), as well as inhaled nitric oxide as a future treatment for neonatal pulmonary hypertension.
As Professor of Medicine, Sheffield University, he established the national network of accredited centres for the treatment of pulmonary hypertension, and led an international programme to construct the first “virtual lung” for the study of pharmacology of inhaled therapies. Later, as Corporate Clinical Director of Chiesi Farmaceutici, Tim began the development of the first triple inhaler for COPD, Trimbow.